Flamingo-1: Germany’s First Space-Based SDA Telescope Delivers Commercial Space Surveillance and Tracking

29.10.2026 10:22:14 CET | news aktuell GmbH | Press Release

Share

Munich, October 29th, 2026 – Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has entered routine operations with its Flamingo-1 satellite. The satellite operates at a high duty cycle, continuously monitoring space objects, scouting for threats from low Earth orbit (LEO) to geostationary Earth orbit (GEO). The space-based image data generated by Flamingo-1 is further processed by Vyoma into products, services and intelligence in high demand among the SDA community and Vyoma’s customers to better understand the space domain from both a safety and a security perspective. The information is delivered to the company’s customers through the Vyoma Services Platform.

Flamingo-1 operates both in surveillance and in tracking mode. In surveillance mode, the satellite continuously screens a large volume of space, setting it apart from ground-based optical systems that are idle during the day or when obstructed by bad weather. This high volume of data is ideal for creating and maintaining a catalogue of space objects, capturing satellite manoeuvres, and observing newly inserted objects into orbit quickly.

In tracking mode, Flamingo-1 follows a predefined trajectory to observe objects of interest, such as military targets, close approaches of other space objects (both accidental and intentional) or payload launcher separations.

About Vyoma

Vyoma builds sovereign space domain awareness (SDA) capabilities for national governments and their partners. Its own space-based surveillance satellite constellation monitors the low Earth orbit to geostationary Earth orbit orbital regime, scouting for threats and tracking objects of interest. Founded in Munich in 2020, Vyoma takes part in European Commission and European Space Agency (ESA) programmes. www.vyoma.space.

Contacts

Klaus Burgmair
Schwartz Public Relations GmbH
kb@schwartzpr.de

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Munich Arena breaks ground, marking a new era for live music in Europe29.10.2026 16:12:11 CET | Press Release

20,000 capacity "Music first" venue: The Munich Arena will be Germany's first concert arena specifically designed for music and live entertainment. The combination of striking architecture, exceptional acoustics, excellent sightlines, premium hospitality and world-class production facilities for artists and promoters will make Munich Arena one of Europe’s leading live music venues. Economic impact of €355 million per year: Munich Arena will boost the economy and culture for Munich and Bavaria, a Deloitte study estimates the economic impact to be around €355 million per year when the venue is open. Countdown to the opening in 2029 has begun: Freising’s lord mayor Monika Schwind joined Marek Lieberberg, President Live Nation GSA, Tom Lynch, President Live Nation Venues, Lorenz Schmid, Managing Partner Munich Arena, and Bavarian Prime Minister Dr. Markus Söder to officially break ground on Munich Arena. A supporter of Munich’s Olympic concept and the Free State of Bavaria:. Munich Arena i

Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain28.10.2026 09:30:00 CET | Press Release

Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.¹ Aachen, Germany, 28 October 2026 – Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand. The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for ret

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye